Lung Function in ILD Patients


Trial Objective

ILD, Interstitial Lung Disease, DLCOThe purpose of this study is to look at the effect of trans sodium crocetinate (TSC) on lung function. It is thought that TSC will improve the body's ability to deliver oxygen to oxygen-deprived tissue. Researchers hope that TSC will improve lung function in people with ILD.


Active Clinical Trials Currently Recruiting

Who Can Participate

People who have been diagnosed with ILD may be eligible to participate in this study.

Age: 30-85    Gender: Any Gender

Estimated Time Commitment

Up to 31 days

he screening period is up to 28 days. The treatment period is one day. A follow up 1 hour phone call visit 48 hours after the treatment period.

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Not Available

Trial Contact

For more information, contact:

Hannah Slowey

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Diffusion Pharmaceuticals, Inc.

Principal Investigators

Request More Information

By completing this form, you agree to learn more about this study and see if you qualify.

 I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: